Patents by Inventor Ian Farquhar Campbell McKenzie

Ian Farquhar Campbell McKenzie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110033493
    Abstract: The present invention provides a method of immunising a subject comprising the step of administering a composition comprising an antigen and a carbohydrate polymer comprising mannose to a mucosal site of the subject, methods of use of the composition for vaccination and sterilization and use of the composition in manufacturing a medicament.
    Type: Application
    Filed: June 11, 2010
    Publication date: February 10, 2011
    Applicants: AUSTIN RESEARCH INSTITUTE, THE, MELBOURNE, UNIVERSITY OF, THE
    Inventors: Ian Farquhar Campbell McKenzie, Geoffrey Allan Pietersz, Christina Cheers, John Stambas
  • Publication number: 20100119514
    Abstract: An isolated binding partner of a Cripto-1 protein, Pim-1 protein or an antigen present in a colon cancer cell lysate is described. The binding partner inhibits growth of one or more cancer cell types and may be used in an anti-cancer agent for treating cancer in a subject. The binding partner may also be used in a method of inducing apoptosis in a cancer cell, as well as in a method of sensitising a cancer cell to a cytotoxic compound. In addition, a cancer vaccine is described wherein the vaccine comprises a Cripto-1 protein (or an antigenic fragment thereof), Pim-1 protein (or an antigenic fragment thereof) or an antigen present in a colon cancer cell lysate or, alternatively, comprises an expressible DNA molecule encoding a Cripto-1 protein (or an antigenic fragment thereof), Pim-1 protein (or an antigenic fragment thereof) or an antigen present in a colon cancer cell lysate.
    Type: Application
    Filed: November 16, 2009
    Publication date: May 13, 2010
    Applicant: The Macfarlane Burnet Institute for Medical Research and Public Health Ltd.
    Inventors: Ian Farquhar Campbell McKenzie, Pei Xiang Xing, Xiu Feng Hu
  • Publication number: 20090317414
    Abstract: A cancer vaccine, and a composition for the ex vivo priming of dendritic cells, is disclosed which comprises a MUC1 T cell epitope-derived peptide or peptide analogue capable of provoking a cytotoxic T cell immune response. Particular MUC1 T cell epitope-derived peptides disclosed include TTAPPVHGL, STAPPVHGL, STAPPAHGL, TTAPPAHGV and SAPDTYPAL.
    Type: Application
    Filed: July 25, 2007
    Publication date: December 24, 2009
    Applicant: 4G VACCINES PTY LTD
    Inventors: Geoffrey Allan Pietersz, Vasso Apostolopoulos, Ian Farquhar Campbell McKenzie
  • Publication number: 20090123470
    Abstract: An isolated binding partner of a Cripto-1 protein, Pim-1 protein or an antigen present in a colon cancer cell lysate is described. The binding partner inhibits growth of one or more cancer cell types and may be used in an anti-cancer agent for treating cancer in a subject. The binding partner may also be used in a method of inducing apoptosis in a cancer cell, as well as in a method of sensitizing a cancer cell to a cytotoxic compound. In addition, a cancer vaccine is described wherein the vaccine comprises a Cripto-1 protein (or an antigenic fragment thereof), Pim-1 protein (or an antigenic fragment thereof) or an antigen present in a colon cancer cell lysate or, alternatively, comprises an expressible DNA molecule encoding a Cripto-1 protein (or an antigenic fragment thereof), Pim-1 protein (or an antigenic fragment thereof) or an antigen present in a colon cancer cell lysate.
    Type: Application
    Filed: November 20, 2007
    Publication date: May 14, 2009
    Applicant: The Macfarlane Burnet Istitute for Medical Research and Public Health Ltd.
    Inventors: Ian Farquhar Campbell McKenzie, Pei Xiang Xing, Xiu Feng Hu
  • Patent number: 7318924
    Abstract: An isolated binding partner of a Cripto-1 protein, Pim-1 protein or an antigen present in a colon cancer cell lysate is described. The binding partner inhibits growth of one or more cancer cell types and may be used in an anti-cancer agent for treating cancer in a subject. The binding partner may also be used in a method of inducing apoptosis in a cancer cell, as well as in a method of sensitizing a cancer cell to a cytotoxic compound. In addition, a cancer vaccine is described wherein the vaccine comprises a Cripto-1 protein (or an antigenic fragment thereof), Pim-1 protein (or an antigenic fragment thereof) or an antigen present in a colon cancer cell lysate or, alternatively, comprises an expressible DNA molecule encoding a Cripto-1 protein (or an antigenic fragment thereof), Pim-1 protein (or an antigenic fragment thereof) or an antigen present in a colon cancer cell lysate.
    Type: Grant
    Filed: March 26, 2002
    Date of Patent: January 15, 2008
    Assignee: The Austin Research Institute
    Inventors: Ian Farquhar Campbell McKenzie, Pei-Xiang Xing, Xiu Feng Hu
  • Patent number: 7001998
    Abstract: The invention relates to nucleic acids which encode glycosyltransferase and are useful in producing cells and organs from one species which may be used for transplantation into a recipient of another species. It also relates to the production of nucleic acids which, when present in cells of a transplanted organ, result in reduced levels of antibody recognition of the transplanted organ.
    Type: Grant
    Filed: August 1, 1997
    Date of Patent: February 21, 2006
    Assignee: The Austin Research Institute
    Inventors: Ian Farquhar Campbell McKenzie, Mauro Sergio Sandrin
  • Publication number: 20040213781
    Abstract: The present invention generally relates to molecules having Fc binding ability such as those with Fc receptor-like activity. The present invention also relates to the molecules, nucleic acids encoding the molecules, antagonist compounds, pharmaceutical compositions comprising the molecules and compounds, methods for testing potential antagonists, methods for producing the polypeptides, methods of treatment of disease and other aspects.
    Type: Application
    Filed: July 31, 2003
    Publication date: October 28, 2004
    Inventors: Phillip Mark Hogarth, Ian Farquhar Campbell McKenzie, Ross Ian Baker, Mark Darren Hulett, Maree Sharne Powell
  • Publication number: 20020081654
    Abstract: A nucleic acid construct encoding a peptide with hydrolase activity and a heterologous localization signal which locates the peptide, upon expression of the construct in a cell, to a cellular location proximal to the cellular site of a glycosylated agent or a glycosylating agent. The construct can be used to produce, for example, organs suitable for transplantation which show reduced levels of the epitope Gal&agr;(1,3)Gal.
    Type: Application
    Filed: April 6, 2001
    Publication date: June 27, 2002
    Inventors: Mauro Sergio Sandrin, Ian Farquhar Campbell McKenzie, Narin Osman
  • Publication number: 20010055584
    Abstract: The invention relates to nucleic acids which encode glycosyltransferase and are useful in producing cells and organs from one species which may be used for transplantation into a recipient of another species. It also relates to the production of nucleic acids which, when present in cells of a transplanted organ, result in reduced levels of antibody recognition of the transplanted organ.
    Type: Application
    Filed: March 31, 1998
    Publication date: December 27, 2001
    Inventors: IAN FARQUHAR CAMPBELL MCKENZIE, MAURO SERGIO SANDRIN
  • Patent number: 5798097
    Abstract: Immunoglobulin conjugates, comprising idarubicin (Ida) conjugated to a monoclonal antibody or fragment thereof comprising at least one of the antigen binding sites of the antigen, are useful for treating a human or other animal suffering from a cancer or for depleting a subset of T lymphocytes from a population of cells.
    Type: Grant
    Filed: April 11, 1995
    Date of Patent: August 25, 1998
    Assignee: Pharmacia & Upjohn S.p.A.
    Inventors: Ian Farquhar Campbell McKenzie, Geoffrey Allan Pietersz, Mark John Smyth